Data showed that STK39 inhibitors significantly decreased the cell viability of HCC cells and inhibited the phosphorylation of STK39, PLK1 and ERK1/2 (Figure 7D-G) 43, 47. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.